---
title: "Mayinglong Pharmaceutical Group Co., Ltd (600993.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/600993.SH.md"
symbol: "600993.SH"
name: "Mayinglong Pharmaceutical Group Co., Ltd"
industry: "Pharmaceuticals"
datetime: "2026-04-17T02:14:53.941Z"
locales:
  - [en](https://longbridge.com/en/quote/600993.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/600993.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/600993.SH.md)
---

# Mayinglong Pharmaceutical Group Co., Ltd (600993.SH)

## Company Overview

Mayinglong Pharmaceutical Group Co., Ltd., together with its subsidiaries, manufactures and sells Chinese and Western medicines in China and internationally. The company offers functional cosmetics, functional care products and food, Chinese herbal medicines, and medical devices. It also manufactures, processes, and sells medicinal packaging materials, cosmetics, and Chinese medicines; and offers first and second category medical devices, household products, electronic products, daily necessities, hygiene products, and disinfection products, as well as automobile freight services. In addition, the company is involved in the retail and wholesale of medical devices and medicines; provision of hospital and medical management service; and hospital operations.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.mayinglong.cn](https://www.mayinglong.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-04-16T04:30:12.000Z

**Overall: B (0.29)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 32 / 221 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 8.36% |  |
| Net Profit YoY | 18.50% |  |
| P/B Ratio | 2.54 |  |
| Dividend Ratio | 2.45% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 10926431287.12 |  |
| Revenue | 3774706696.51 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 13.77% | B |
| Profit Margin | 15.15% | A |
| Gross Margin | 48.14% | B |
| Revenue YoY | 8.36% | B |
| Net Profit YoY | 18.50% | B |
| Total Assets YoY | 4.23% | C |
| Net Assets YoY | 7.29% | B |
| Cash Flow Margin | 110.24% | B |
| OCF YoY | 8.36% | B |
| Turnover | 0.72 | B |
| Gearing Ratio | 17.03% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Mayinglong Pharmaceutical Group Co., Ltd",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "8.36%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "18.50%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.54",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "2.45%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "10926431287.12",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "3774706696.51",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "13.77%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "15.15%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "48.14%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "8.36%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "18.50%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "4.23%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "7.29%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "110.24%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "8.36%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.72",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "17.03%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 18.92 | 30/221 | 22.67 | 21.42 | 20.39 |
| PB | 2.52 | 103/221 | 2.89 | 2.82 | 2.71 |
| PS (TTM) | 2.87 | 62/221 | 3.28 | 3.19 | 3.05 |
| Dividend Yield | 2.47% | 40/221 | 2.32% | 2.20% | 1.46% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | B | B | A |
| 02 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 03 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 04 | Salubris (002294.SZ) | B | C | C | A | B | B |
| 05 | Haisco (002653.SZ) | B | B | B | B | A | B |

## Institutional View

### Analyst Rating Distribution

> As of 2025-10-30T16:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 24.68 |
| Highest Target | 38.50 |
| Lowest Target | 33.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/600993.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/600993.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/600993.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/600993.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**